A Twelve-Month, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Comparing the Efficacy and Safety of Brolucizumab 6 mg Versus Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
Fields of Study & Subjects
Retinal Diseases and Treatments
Ocular Diseases and Behçet’s Syndrome
Retinal and Macular Surgery
Publication details
- Journal / source
- Vivli
- Publication date
- 27 March 2026
- Language
- EN
- Document type
- Dataset